Ruibing Lyu1, Wen Wang2, Wenju Wang1, Nian Liu3, Jinwen Xiao1, Xin Li1. 1. Department of PCCM, CR & WISCO General Hospital, Wuhan University of Science and Technology No. 29, Metallurgical Avenue, Qingshan District, Wuhan 430080, Hubei Province, P. R. China. 2. Department of Rehabilitation, CR & WISCO General Hospital, Wuhan University of Science and Technology No. 29, Metallurgical Avenue, Qingshan District, Wuhan 430080, Hubei Province, P. R. China. 3. Department of Clinical Medicine, School of Medicine, Wuhan University of Science and Technology 50 m Northeast of The Intersection of Heping Avenue and Xueyuan Road, Wuhan 430080, Hubei Province, P. R. China.
Abstract
OBJECTIVE: To investigate the effect of humidified high-flow nasal cannula oxygen therapy (HFNC) on the application effect and respiratory functional recovery of stable COPD patients. METHODS: The data of 116 patients with stable COPD treated in our hospital from March 2019 to January 2021 were analyzed retrospectively. Among them, 54 patients treated with conventional oxygen therapy (COT) were enrolled into the control group (CG), and the remaining 62 treated with HFNC were divided to the experimental group (EG). The clinical efficacy and adverse reactions of both groups were assessed, and the blood gas analysis indexes pH, PaO2, PaCO2, respiratory function indexes FEV1, FEV1%, FEV1/FVC, quality of life and motor recovery were compared. RESULTS: After treatment, compared with the CG, the FEV1, FEV1% and FEV1/FVC in the EG were obviously higher (P<0.05). Besides, the pH and PaO2 in the EG were markedly higher (P<0.05), while PaCO2 was lower (P<0.05). The total effective rate, SGRQ scores and 6MWT in the EG were markedly higher than those in the CG (P<0.05), while the incidence of adverse reactions in the EG was lower (P<0.05). CONCLUSION: HFNC can improve respiratory function and quality of life of stable COPD patients, with higher safety. AJTR
OBJECTIVE: To investigate the effect of humidified high-flow nasal cannula oxygen therapy (HFNC) on the application effect and respiratory functional recovery of stable COPD patients. METHODS: The data of 116 patients with stable COPD treated in our hospital from March 2019 to January 2021 were analyzed retrospectively. Among them, 54 patients treated with conventional oxygen therapy (COT) were enrolled into the control group (CG), and the remaining 62 treated with HFNC were divided to the experimental group (EG). The clinical efficacy and adverse reactions of both groups were assessed, and the blood gas analysis indexes pH, PaO2, PaCO2, respiratory function indexes FEV1, FEV1%, FEV1/FVC, quality of life and motor recovery were compared. RESULTS: After treatment, compared with the CG, the FEV1, FEV1% and FEV1/FVC in the EG were obviously higher (P<0.05). Besides, the pH and PaO2 in the EG were markedly higher (P<0.05), while PaCO2 was lower (P<0.05). The total effective rate, SGRQ scores and 6MWT in the EG were markedly higher than those in the CG (P<0.05), while the incidence of adverse reactions in the EG was lower (P<0.05). CONCLUSION: HFNC can improve respiratory function and quality of life of stable COPD patients, with higher safety. AJTR
Authors: Yinglin Wu; Shiyu Zhang; Bingting Zhuo; Miao Cai; Zhengmin Min Qian; Michael G Vaughn; Stephen Edward McMillin; Zilong Zhang; Hualiang Lin Journal: Environ Sci Pollut Res Int Date: 2022-01-12 Impact factor: 4.223
Authors: Ali Albarrati; Ibrahim Hazazi; Ali H Alnahdi; Mohammed Taher; Rakan Nazer; Hassan Alrefaee Journal: Disabil Rehabil Date: 2022-02-27 Impact factor: 3.033
Authors: Matthew Moll; Adel Boueiz; Auyon J Ghosh; Aabida Saferali; Sool Lee; Zhonghui Xu; Jeong H Yun; Brian D Hobbs; Craig P Hersh; Don D Sin; Ruth Tal-Singer; Edwin K Silverman; Michael H Cho; Peter J Castaldi Journal: Am J Respir Crit Care Med Date: 2022-01-15 Impact factor: 21.405